Véronique Guerin‐Meyer

Author

Also Known As

Mohamed Gasmi, V. Guerin-Meyer, V. Guérin-Meyer, Veronique Guerin-Meyer, Veronique I. Guerin-Meyer, Véronique Guérin-Meyer, Vincent Hautefeuille, Véronique Guerin-Meyer, Véronique Guerin‐Meyer, Véronique Guérin-Meyer

Publications

Citations

H-Index

Concepts

All Affiliations

Institut de Cancérologie de l'Ouest Inserm Centre Hospitalier Départemental Vendée Sorbonne Université Centre Eugène Marquis

About

Véronique Guerin‐Meyer is an author at Institut de Cancérologie de l'Ouest specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	214
2	Health Sciences	2	2	24
3	Public Health	1	1	15
4	Gastroenterology	1	1	13
5	Nephrology	1	1	13

Véronique Guerin‐Meyer

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study Julien Edeline, M. Benabdelghani, Aurélie Bertaut, Journal of Clinical Oncology	2019	504
Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions Laurence Gamelin, M. Boisdron‐Celle, R. Delva, Clinical Cancer Research	2004	342
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803 Olivier Bouché, Jean‐Luc Raoul, Franck Bonnetain, Journal of Clinical Oncology	2004	278
Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage Érick Gamelin, M. Boisdron‐Celle, Véronique Guerin‐Meyer, Journal of Clinical Oncology	1999	204
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach M. Boisdron‐Celle, Olivier Capitain, Roger Faroux, Seminars in Oncology Preclinical Drug EvaluationPharmacologyToxicologyPharmacotherapyMetabolomics	2017	78
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study Hugues Bourgeois, Françoise Grudé, P. Solal-Céligny, Annals of Oncology Prognostic AssessmentMedicineCancer ManagementPrognosisOutcomes Research	2017	47
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials Thomas Aparicio, Michel Ducreux, Roger Faroux, European Journal of Cancer ObesityFfcd TrialsGastrointestinal OncologyMedicineCancer Management	2018	39
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients Cindy Serdjebi, Johan Gagnière, Jérôme Desrame, PLoS ONE	2015	22
Humoral hypercalcemia in patients with colorectal carcinoma Alain Lortholary, Sophie D. Cadeau, G. Bertrand, Cancer	1999	21
Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol Alice Boilève, Aline Maillard, Mathilde Wagner, BMC Cancer	2020	18

Page 1